(Display images as block.) |
(Reduce size of scroll arrow) |
||
Line 35: | Line 35: | ||
height: auto; | height: auto; | ||
width: 150px; | width: 150px; | ||
+ | } | ||
+ | |||
+ | img.scroll-ico { | ||
+ | height: auto; | ||
+ | width: 50px; | ||
} | } | ||
Line 66: | Line 71: | ||
</div> | </div> | ||
− | <div style="margin:auto;"> | + | <div class="scroll-ico" style="margin:auto;"> |
<a href="#start"> | <a href="#start"> | ||
<img src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png"> | <img src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png"> |
Revision as of 04:21, 15 October 2017
![CATE logo](https://static.igem.org/mediawiki/2017/d/d6/T--ETH_Zurich--LogoMinimal.png)
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more![](https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png)
![](https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png)
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.
We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor
![](https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png)
The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.
Design